New Sanofi Efpeglentatide vs. Trulicity Study Initiated

A new CT.gov record for a superiority study evaluating efpeglentatide vs. Trulicity (AMPLITUDE-D) has been observed. The trial appears to be similar to Novo’s SUSTAIN 7 (Ozempic vs. Trulicity) where Ozempic was shown to be superior to Trulicity in terms of glycemic control and weight loss. Below, FENIX provides thoughts on AMPLITUDE-D and Sanofi’s potential strategy to avoid a H2H study vs. Novo’s Ozempic.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.